Current trends in essential thrombocythaemia

Same author

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

British journal of haematology·2026

Same author

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Blood advances·2026

Same author

Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.

Cancer medicine·2026

Same author

Combination treatments for myelofibrosis in JAK inhibitor-naive patients: evidence, rationale, and clinical direction.

Expert opinion on pharmacotherapy·2026

Same author

Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit control.

Therapeutic advances in hematology·2026

Same author

GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study.

Haematologica·2026

Same journal

The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.

British journal of haematology·2026

Same journal

Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.

British journal of haematology·2026

Same journal

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

British journal of haematology·2026

Same journal

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

British journal of haematology·2026

Same journal

Evaluating high-sensitivity troponin levels in people with sickle cell disease in the emergency department.

British journal of haematology·2026

Same journal

Methaemoglobinaemia: From pathophysiology to contemporary clinical management.

British journal of haematology·2026

Related Experiment Videos

Current trends in essential thrombocythaemia

Related Concept Videos

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.

Combination treatments for myelofibrosis in JAK inhibitor-naive patients: evidence, rationale, and clinical direction.

Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit control.

GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study.

The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.

Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

Evaluating high-sensitivity troponin levels in people with sickle cell disease in the emergency department.

Methaemoglobinaemia: From pathophysiology to contemporary clinical management.

Related Experiment Videos

Current trends in essential thrombocythaemia

Related Concept Videos

Related Articles

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.

Combination treatments for myelofibrosis in JAK inhibitor-naive patients: evidence, rationale, and clinical direction.

Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit control.

GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study.

The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.

Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

Evaluating high-sensitivity troponin levels in people with sickle cell disease in the emergency department.

Methaemoglobinaemia: From pathophysiology to contemporary clinical management.